ProQR Therapeutics NV (MEX:PRQRN) LT-Debt-to-Total-Asset: 0.09 (As of Mar. 2026)

What is ProQR Therapeutics NV LT-Debt-to-Total-Asset?

ProQR Therapeutics NV MEX:PRQRN 44 LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 44/100 and a GF Value™ of MXN40.07. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ProQR Therapeutics NV's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.09.

ProQR Therapeutics NV's long-term debt to total assets ratio increased from Mar. 2025 (0.07) to Mar. 2026 (0.09). It may suggest that ProQR Therapeutics NV is progressively becoming more dependent on debt to grow their business.

ProQR Therapeutics NV (MEX:PRQRN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ProQR Therapeutics NV LT-Debt-to-Total-Asset Related Terms

ProQR Therapeutics NV LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV LT-Debt-to-Total-Asset Chart

ProQR Therapeutics NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.11

0.13

0.07

0.09

ProQR Therapeutics NV Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.08	0.08	0.09	0.09

44GF Score

ProQR Therapeutics NV MEX:PRQRN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ProQR Therapeutics NV LT-Debt-to-Total-Asset Calculation

ProQR Therapeutics NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	201.289	/	2377.343
	=	0.08

ProQR Therapeutics NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	189.104	/	2064.567
	=	0.09

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.09 mean?

ProQR Therapeutics NV (MEX:PRQRN) has a LT-Debt-to-Total-Asset of 0.09 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ProQR Therapeutics NV and its competitors.

Is ProQR Therapeutics NV's LT-Debt-to-Total-Asset too high?

ProQR Therapeutics NV's current LT-Debt-to-Total-Asset is 0.09. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.

How does ProQR Therapeutics NV's LT-Debt-to-Total-Asset compare to GALT and HRTX?

ProQR Therapeutics NV's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ProQR Therapeutics NV stock overvalued right now?

ProQR Therapeutics NV (MEX:PRQRN) has a current LT-Debt-to-Total-Asset of 0.09. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.

Key valuation signals for MEX:PRQRN:

LT-Debt-to-Total-Asset: 0.09
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Industry Healthcare Biotechnology

Comparable Companies GALT HRTX PLYX ORMP SPRO PLX MENS NRXP OKUR MIST VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges PRQR:USA 0PQ:Germany

Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK

Website https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

44GF Score

Get the complete analysis for MEX:PRQRN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00

Price

MXN40.07

GF Value

View MEX:PRQRN Analysis

See LT-Debt-to-Total-Asset data for all stocks →